ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 933,16
-0,65%
Dow Jones
38 023,37
0,32%
DAX
17 945,81
0,13%
Brent Oil
83,375
-0,20%
Bitcoin
58 449,87
0,36%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Canadá
  5. TSXV
  6. Nurexone Biologic Inc (NRX)

  7. Nurexone Biologic Inc (NRX) Actualités

NRX Nurexone Biologic Inc

0,62
0,02 (3,33%)
Dernière mise à jour : 15:30:00
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Nurexone Biologic Inc NRX TSX Venture Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,02 3,33% 0,62 15:30:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,62 0,62 0,62 0,60
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
25/4/202417:30APSShares of Biopharma Up After News of Uplisting
25/4/202414:35GLOBENurExone Biologic Inc. Announces Strategic Expansion to US..
19/4/202422:04GLOBENurExone Presenting on Revolutionary Spinal Cord Injury..
02/4/202414:31GLOBENurExone Reports Fourth Quarter and Year Ended December 31,..
27/3/202422:05GLOBEGross Proceeds Close of $4M CAD Generated for NurExone From..
22/3/202422:04GLOBEIn Preparation for Expected Human Clinical Trials, NurExone..
15/3/202421:05GLOBENurExone's Strategic Update: Submission of OTCQB Listing..
08/3/202422:05GLOBENurExone establishing State-of-the-Art Research and..
01/3/202422:04GLOBENurExone Presenting Novel Regulatory Pathways for Exosomes..
20/2/202422:05GLOBENurExone’s Intellectual Property Portfolio Expands
14/2/202422:20GLOBENurExone Launches Licensing Efforts for ExoTherapy Platform
02/2/202422:05GLOBENurexone Biologic Initiates European Orphan Drug Designation..
17/1/202414:34GLOBENurExone and Inteligex Kick Off Chronic Spinal Cord Injury..
05/1/202414:30GLOBENurExone Announces Closing of a Private Placement for Gross..
29/11/202314:30GLOBENurExone Biologic Extends Spinal Cord Injury Therapy..
24/11/202314:30GLOBENurExone Reports Third Quarter 2023 Financial Results and..
16/11/202322:21APSTake Part in the Next Generation of Spinal Cord Injury..
07/11/202322:01APSOrphan Drugs Worth $64 Billion by 2028 and This Micro Cap..
31/10/202322:00APSWhen Technicals and Fundamentals Converge, A Nice Uptrend..
30/10/202318:00APSShares Up Following Orphan Drug Designation
30/10/202314:20GLOBENurExone Biologic Receives FDA Orphan-Drug Designation,..
25/10/202323:18APSMicrocap Offers Unique Opportunity for Investors In $10..
19/10/202314:30GLOBEAppointment of Professor Teo Forcht Dagi to Scientific..
18/10/202323:07APSNew Collaboration Could Revolutionize Treatment of Chronic..
11/10/202316:00APSSmall Company Working on Big Breakthrough in Treating Spinal..
11/10/202314:30GLOBENurExone Secures Eureka Grant for Collaborative..
05/10/202314:30GLOBENurExone Biologic to Present Exosome-Based Therapy for..
28/9/202314:30GLOBENurExone Appoints Dr. Reuter Investor Relations in Europe
13/9/202314:30GLOBENurExone Moves Forward Towards Human Clinical Trials,..
06/9/202314:30GLOBENurExone Announces Closing of Second Tranche of Private..
09/8/202314:00GLOBENurExone Announces Private Placement
20/7/202314:15GLOBENurExone Biologic Announces Advancements in Extracellular..
22/6/202314:00GLOBERegeneration and Reinnervation of Spinal Cord in Rats..
01/6/202314:00GLOBENurExone and Particle Metrix Announce Collaboration in..
16/5/202314:30GLOBENurExone Granted U.S. Patent for Technology and Drug..

Dernières Valeurs Consultées

TSXV
NRX
Nurexone Biologic
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés